| __timestamp | Madrigal Pharmaceuticals, Inc. | TG Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 15746000 | 24518692 |
| Thursday, January 1, 2015 | 13392000 | 19886580 |
| Friday, January 1, 2016 | 9290000 | 12631689 |
| Sunday, January 1, 2017 | 7672000 | 21977998 |
| Monday, January 1, 2018 | 15293000 | 20759000 |
| Tuesday, January 1, 2019 | 22648000 | 20838000 |
| Wednesday, January 1, 2020 | 21864000 | 121812000 |
| Friday, January 1, 2021 | 37318000 | 152137000 |
| Saturday, January 1, 2022 | 48130000 | 83231000 |
| Sunday, January 1, 2023 | 108146000 | 122706000 |
Data in motion
In the ever-evolving landscape of biopharmaceuticals, operational efficiency is paramount. Over the past decade, Madrigal Pharmaceuticals, Inc. and TG Therapeutics, Inc. have demonstrated contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Madrigal's SG&A expenses surged by over 580%, peaking in 2023. This reflects their aggressive expansion and investment in operational capabilities. In contrast, TG Therapeutics experienced a more volatile trajectory, with a notable spike in 2020, where expenses increased by over 500% compared to 2019, likely due to strategic shifts or product launches. By 2023, TG Therapeutics' SG&A expenses were approximately 13% higher than Madrigal's, indicating a potential focus on scaling operations. These trends underscore the dynamic nature of the biopharma sector, where strategic financial management can significantly impact a company's market position.
Breaking Down SG&A Expenses: Johnson & Johnson vs TG Therapeutics, Inc.
Breaking Down SG&A Expenses: argenx SE vs Madrigal Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Madrigal Pharmaceuticals, Inc.
Comparing SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs Opthea Limited Trends and Insights
Madrigal Pharmaceuticals, Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Madrigal Pharmaceuticals, Inc. and ImmunityBio, Inc.
Who Optimizes SG&A Costs Better? Madrigal Pharmaceuticals, Inc. or MannKind Corporation
Madrigal Pharmaceuticals, Inc. or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Madrigal Pharmaceuticals, Inc. and Xencor, Inc.
Operational Costs Compared: SG&A Analysis of TG Therapeutics, Inc. and MorphoSys AG
Who Optimizes SG&A Costs Better? TG Therapeutics, Inc. or Agios Pharmaceuticals, Inc.
Comparing SG&A Expenses: TG Therapeutics, Inc. vs Celldex Therapeutics, Inc. Trends and Insights